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OBJECTIVEdCompelling biological pathways suggest that selenium (Se) may lower onset of
type 2 diabetes mellitus (T2DM), but very few studies have evaluated this relationship, with
mixed results. We examined the association between toenail Se and incidence of T2DM.
RESEARCH DESIGN AND METHODSdWe performed prospective analyses in two
separate U.S. cohorts, including 3,630 women and 3,535 men, who were free of prevalent
T2DM and heart disease at baseline in 1982–1983 and 1986–1987, respectively. Toenail Se
concentration was quantiﬁed using neutron activation analysis, and diabetes cases were iden-
tiﬁed by biennial questionnaires and conﬁrmed by a detailed supplementary questionnaire.
Hazard ratios of incident T2DM according to Se levels were calculated using Cox proportional
hazards.
RESULTSdDuring 142,550 person-years of follow-up through 2008, 780 cases of incident
T2DM occurred. After multivariable adjustment, the risk of T2DM was lower across increasing
quintiles of Se, with pooled relative risks across the two cohorts of 1.0 (reference), 0.91 (95% CI
0.73–1.14), 0.78 (0.62–0.99), 0.72 (0.57–0.91), and 0.76 (0.60–0.97), respectively (P for
trend = 0.01). Results were similar excluding the few individuals (4%) who used Se supplements.
In semiparametric analyses, the inverse relationship between Se levels and T2DM risk appeared
to be linear.
CONCLUSIONSdAt dietary levels of intake, individuals with higher toenail Se levels are at
lower risk for T2DM. Further research is required to determine whether varying results in this
study versus prior trials relate to differences in dose, source, statistical power, residual confounding
factors, or underlying population risk.
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Accumulating evidence indicates thatexcess oxidative stress is a risk factorfor insulin resistance, b-cell dys-
function, impaired glucose tolerance,
and type 2 diabetes mellitus (T2DM) (1–3).
Selenium (Se), an essential trace nutri-
ent, is a critical component of numerous
selenoproteins involved in antioxidant
defense systems, such as glutathione per-
oxidase, which actively protect against
damage from free radicals and reactive ox-
ygen species (4,5). Increased free radical
levels impair glucose-stimulated insulin se-
cretion, decrease gene expression of key
b-cell genes, and induce cell death (2,6–8).
Investigations into the effects of ha-
bitual Se consumption on chronic disease
in humans have been limited by chal-
lenges in accurately assessing Se intake
from dietary questionnaires, due to errors
in recall, geographic variation in Se expo-
sures, and wide variations in Se content of
otherwise similar foods. In this setting,mea-
surements of toenail Se concentrations
provide a valid and objective biomarker
of long-term (;1 year) Se consumption
(9). However, to our knowledge, no prior
investigations have followed large num-
bers of individuals with both biomarker
measures and sufﬁciently long durations
of follow-up to assess development of
T2DM.
Although compelling biological evi-
dence suggests that Se might reduce the
onset of T2DM, results of prior cross-
sectional studies have been conﬂicting.
One prior study observed an inverse as-
sociation between toenail Se and preva-
lent T2DM (10), whereas two other
studies using data from the U.S. National
Health and Nutrition Examination Survey
showed nonlinear positive associations
between serum Se and prevalence of
T2DM(11,12). Such cross-sectional studies
are limited by an inability to assess tempo-
ral relationships, in that diabetes status
could alter Se levels. In two randomized
clinical trials (13,14), Se supplementation
did not reduce the incidence of T2DM.
However, these studies evaluated the ef-
fects of relatively high Se dosages in spe-
ciﬁc high–cancer risk populations rather
than the effects of dietary doses derived
from foods in more general populations.
To our knowledge, no study has prospec-
tively evaluated the relationship between
habitual dietary Se consumption, as as-
sessed through a valid Se biomarker, and
the incidence of T2DM. Therefore, we
prospectively evaluated whether Se con-
sumption, as assessed by an objectively
measured toenail-Se biomarker, was asso-
ciated with lower incidence of T2DM in
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women and men in two separate U.S. co-
hort studies: the Nurses’ Health Study
(NHS) and the Health Professionals Fol-
low-Up Study (HPFS).
RESEARCH DESIGN AND
METHODSdThe population and de-
sign of the NHS and HPFS have pre-
viously been described (15,16). Brieﬂy,
NHS is a prospective cohort study among
121,700 U.S. female registered nurses
aged 30–55 years at enrollment in 1976,
and HPFS is a prospective cohort study
among 51,529U.S.male health profession-
als aged 40–75 years at enrollment in
1986. Members of both cohorts have
been sent questionnaires biennially about
their medical history, risk factors, life-
style, and disease incidence. The current
study included 3,535 HPFS and 3,630
NHS participants with available toenail
Se data from prior or ongoing nested
case-control studies of cancer or cardio-
vascular disease (CVD) who had available
valid covariate information and were
free of prevalent T2DM or heart disease
(stroke, angina pectoris, and myocardial
infarction) at baseline, deﬁned as the
date of toenail sampling. The Harvard
School of Public Health and Brigham
and Women’s Hospital Human Subjects
Committee Review Board approved the
study protocol.
Assessment of toenail Se
concentrations
We assessed toenail Se as an objective
biomarker of long-term Se consumption.
Other potential measures, such as serum
or plasma Se, provide a measure of short-
term exposure (9,17,18). Hair and ﬁnger-
nail Se levels provide relatively long-term
Se status, but these are more likely than
toenails to be inﬂuenced by superﬁcial
contamination such as use of Se-medicated
shampoos (9,17). In both cohorts, partici-
pants were asked to provide toenail clip-
pings from all 10 toes and return them to
the investigators. Follow-up mail requests
were sent to initial nonrespondents. Over-
all, 68% of HPFS participants and 52% of
NHS participants returned toenail samples
in 1986–1987 and 1982–1983, respec-
tively. No differences in the baseline charac-
teristics were observed between participants
supplying and not supplying toenail sam-
ples in both cohorts (data not shown).
Toenail Se concentrations were mea-
sured using neutron activation analysis at
the University of Missouri Research Re-
actor by personnel unaware of the partic-
ipants’ clinical information. Details of
analytical methods and information re-
garding validation of these measures
have previously been reported (9,17–
20). Samples of nail clippings from all
toes were combined, providing a time-
integrated measure of exposure over ap-
proximately the prior year owing to the
elimination half-life of toenail Se, the
growth rate of toenails, and the differen-
tial length of time (distance) from cuticle
synthesis to toenail clipping comparing
the smallest to largest toes. Sample mass
was adequate for neutron-activation anal-
ysis in all participants. Se determinations
were performed in 98 analytical batches
between 2009 and 2011. Potential labo-
ratory drift was controlled by both stan-
dard comparison procedures for neutron
activation analysis and repeated analysis
of representative sample subsets. Intra-
assay coefﬁcients of variation were 2.4%
for Se. We excluded 164 (2%) individuals
with toenail Se concentrations .1.5 mg/g,
which could reﬂect exogenous contamina-
tion or considerable excess ingestion of Se
supplements (9,19,20).
Toenail Se concentrations are valid bio-
markers of Se consumption, responding
to long-term changes in dietary consump-
tion and correlating with whole blood
and serum Se levels (9,17). A single mea-
surement also correlates with future ex-
posure (9,17,21), based on reasonable
within reliability of toenail Se levels over
time (r = 0.48) for levels in clippings ob-
tained 6 years apart (21).
Ascertainment of T2DM
Potential T2DM cases were identiﬁed by
self-report on biennial questionnaires,
and all self-reported cases were conﬁrmed
by a detailed validated supplementary ques-
tionnaire. Cases were diagnosed according
to theNational Diabetes DataGroup criteria
(22) by having at least one of the following:
1) an elevatedplasma glucose concentration
(fasting $7.8 mmol/L [or 140.4 mg/dL],
random $11.1 mmol/L [or 199.8 mg/dL],
or$11.1 mmol/L 2 h after an oral glucose
load) plus at least one symptom related to
diabetes (excessive thirst, polyuria, weight
loss, or hunger), 2) no symptoms but ele-
vated glucose concentrations as deﬁned
above on at least two occasions, or 3) treat-
ment with insulin or oral hypoglycemic
medication. The lower cutoff point for fast-
ing plasma glucose concentrations (7.0
mmol/L) was used for cases identiﬁed after
1998 according to the American Diabetes
Association criteria (23). The validity of the
supplementary questionnaire for diagnos-
ing T2DM was conﬁrmed against medical
record review in subsamples from both the
NHS (98% conﬁrmed) and the HPFS (97%
conﬁrmed) (24,25). For the present ana-
lysis, case diagnosis information of partic-
ipants was included from the date of toenail
sampling through the latest date of adjudi-
cated follow-up in 2008, representing 26
years of follow-up in NHS (1982–1983
through 2008) and 22 years of follow-up
in HPFS (1986–1987 through 2008).
Assessment of covariates
Detailed information on demographics,
risk factors, habitual diet, and other life-
style habits was collected via validated
self-administered questionnaires. We used
the reports closest in time to the collection
of toenail samples from each participant.
Usual dietary habits were assessed with
validated semiquantitative food frequency
questionnaires that inquired about the
usual intake of foods and beverages and
the use of dietary supplements, includ-
ing multivitamins, Se supplements, and
other dietary supplements over the past
12 months. The reproducibility and valid-
ity of the Food Frequency Questionnaire
have previously been reported (26,27).
Smoking status was assessed as never, for-
mer, and current (1–14, 15–34, and $35
cigarettes per day). Self-reported height
was obtained from the baseline question-
naire. Information on weight was obtained
at baseline, and self-reported weight was
updated every 2 years; self-reported weight
was validated against technician-measured
weight (r = 0.96) among both men and
women in these cohorts (28). In a validation
study, self-reported weight was, on average,
1.0 kg lower than technician-measured
weight (28).
BMI was calculated as the ratio of
weight in kilograms to the square of height
in meters. Physical activity was assessed as
MET tasks per week, using the 1986 HPFS
questionnaire. In theNHS, physical activity
levels were evaluated qualitatively (rather
than as METs) in 1980 and 1982. To min-
imizemisclassiﬁcation yet still capture phys-
ical activity at or before the time of toenail
sampling,we calculated the average physical
activity level in the NHS based on the
average of information from the 1980 and
1982 questionnaires (29). We used sex-
speciﬁc quintiles of physical activity for
the multivariate analyses models.
Statistical analyses
The Cox proportional hazards model was
used to estimate the hazard ratio (hereaf-
ter referred to as relative risk [RR]) of
incident T2DM according to Se levels.
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Person-months of follow-up accrued
from the date of toenail sample return
until the diagnosis of T2DM, death, or
latest date of adjudicated follow-up in
2008dwhichever occurred ﬁrst. Partici-
pants were classiﬁed into sex-speciﬁc
quintiles of toenail Se. In preliminary
analyses, the relationships between toe-
nail Se and incident T2DM did not differ
according to sample selection status (con-
trol subjects vs. future case subjects in
nested prospective case-control studies
of cancer or CVD), smoking status (P =
0.69), or sex (P = 0.85). To account for
geographic variation in Se exposures, U.S.
states were grouped into ﬁve regions
based on other analyses to increase inter-
pretability and minimize confounding by
geographic location (30). To minimize
other potential confounding factors, we
evaluated three covariate models: model 1,
adjusted for age, sex, and future case sta-
tus; model 2, further adjusted for other
environmental and lifestyle factors, in-
cluding geographic region, smoking, al-
cohol intake, physical activity, BMI, and
use of Se ormultivitamin supplements; and
model 3, further adjusted for other dietary
risk factors for T2DM including consump-
tion of total energy, trans fat, whole grains,
coffee, and the ratio of polyunsaturated to
saturated fat. Potential effect modiﬁcation
was assessed by sex, smoking, time, and
sample selection status (control subjects
vs. future case subjects in nested prospec-
tive case-control studies of cancer or CVD).
We included multiplicative terms in the
Cox regression models, with adjustment
for other potential confounders. The me-
dian value of each Se-level category was
evaluated as a continuous variable to test
for linear trends. Nonlinear relation-
ships were examined semiparametrically
using restricted cubic splines, excluding
values outside the 5th and 95th percen-
tiles. All P values were two tailed, a = 0.05.
Analyses were performed using SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTSdBaseline characteristics of
the cohorts, including 3,535 men and
3,630 women, are presented in Table 1.
The mean concentration of toenail Se was
0.84 mg/g in men and 0.77 mg/g in
women. Use of Se supplements was infre-
quent, including only 6% of men and 3%
of women. General multivitamin supple-
ment use was more common, taken by
35% of men and 38% of women.
Individuals with higher Se levels con-
sumed more whole grains and less satu-
rated fat, coffee, andalcohol (Supplementary
Table). They were also less likely to be
current smokers, and geographic variation
in Se levels was also seen, as previously
reported (30). We therefore adjusted for
these and other potential confounding fac-
tors in multivariable models.
During 142,550 person-years of follow-
up, we documented 780 cases of incident
T2DM. Higher toenail Se levels were as-
sociated with lower risk of incident T2DM
in both men and women (Table 2). After
multivariate adjustment for age, sex, geo-
graphic region, smoking, alcohol intake,
physical activity, BMI, Se supplement
use, multivitamin use, and dietary risk fac-
tors for T2DM, Se levels were inversely as-
sociated with incidence of T2DM, with
pooled RRs of T2DM across increasing
quintiles of Se of 1.0 (reference), 0.91
(95% CI 0.73–1.14), 0.78 (0.62–0.99),
0.72 (0.57–0.91), and 0.76 (0.60–0.97)
in both cohorts combined (P for trend =
0.01). Spline analyses suggested mono-
tonic dose-response relationships between
Se and the incidence of T2DM in both
men and women, although the CIs broad-
ened at the highest Se levels owing to fewer
numbers of participants at the extremes
Table 1dBaseline characteristics of the NHS and the HPFS populations
Participant characteristics HPFS (men) NHS (women)
N 3,535 3,630
Toenail Se (mg/g) 0.84 6 0.15 0.77 6 0.13
Age (years) 59.6 6 8.8 52.6 6 6.4
Dietary intake
Total energy (kcal/day) 2,030 6 627 1,743 6 526
Saturated fat intake (g/day) 25.0 6 6.3 21.8 6 4.8
Polyunsaturated fat intake (g/day) 13.0 6 3.5 11.5 6 3.1
Trans fat intake (g/day) 2.9 6 1.1 3.3 6 1.1
Whole-grain intake (g/day) 21.2 6 18.7 14.3 6 13.2
Coffee intake (servings/day) 0.9 6 1.3 2.0 6 1.7
Alcohol intake (g/day) 12.3 6 16.4 7.6 6 12.7
Se supplement use (yes) 214 (6) 101 (3)
Multivitamin supplement use (pills/week)a
None 1,974 (56) 2,110 (58)
1–5 351 (10) 454 (13)
6–9 715 (20) 763 (21)
$10 161 (5) 143 (4)
Geographic regionb
West 748 (21) 505 (14)
Midwest/North 560 (16) 273 (8)
South 610 (17) 271 (7)
Midwest/South 758 (21) 396 (11)
Northeast and other 859 (24) 2,185 (60)
Smoking statusa
Never 1,410 (40) 1,260 (35)
Former 1,599 (45) 936 (26)
Current (1–14/day) 107 (3) 413 (11)
Current (15–34/day) 217 (6) 861 (24)
Current ($35/day) 77 (2) 158 (4)
Physical activity (quintiles)c 3.0 6 1.4 2.9 6 1.4
BMI (kg/m2)a
,22 357 (10) 970 (27)
22 to #25 1,208 (34) 1,084 (30)
25 to #30 1,690 (48) 993 (27)
$30 280 (8) 504 (14)
Data are means6 SD or n (%). aThere are missing data, so the total n counts are not identical. bGeographical
region was grouped based on the Se levels and locations. West: AZ, CA, CO, ID, MT, NM, NV, OR, UT, WA,
WY, and HI. Midwest/North: IA, KS, MI, ND, NE, SD,WI, and MN. South: AL, FL, LA, MS, TN, TX, AR, GA,
and OK. Midwest/South: IL, IN, KY, MO, VA, SC, NC, OH, and WV. Northeast and other: DE, MD, NJ, DC,
AK, CT, GU, MA, ME, MI, NH, NY, PA, PR, PI, VI, and VT. cMETs per week were calculated in men, whereas
the average recreational physical activity levels were assessed qualitatively in women (ref. 29). Reported
values are the means of physical activity quintile levels (1–5) in each study.
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(Fig. 1). No signiﬁcant interactions were
observed between toenail Se and incidence
of T2DM according to other covariates,
including sex, smoking, time, and sample
selection status (P for interaction .0.05
for each).
CONCLUSIONSdIn these two large
prospective U.S. cohorts including both
men and women, higher toenail Se levels
were associated with a lower risk for de-
velopment of T2DM. The dose-response
relationship appeared generally linear or
monotonic at these ranges of toenail Se
levels, without evidence for higher risk at
higher Se levels, although modestly less
beneﬁt at the highest levels could not be
excluded.
Prior studies have reported conﬂicting
results for the relationships between Se and
T2DM. Three previous cross-sectional an-
alyses have shown mixed results (10–12).
Post hoc analyses of two recent random-
ized clinical trials found no beneﬁt of
Se supplementation on incident T2DM.
In the Se and Vitamin E Cancer Preven-
tion Trial (SELECT) (14), Se supplemen-
tation (Se 200 mg/day L-selenomethionine
or mixed form with vitamin E 400 IU/
day rac-a-tocopheryl acetate) had no
signiﬁcant effect on incidence of T2DM
(2,753 cases; RR 1.07 [95% CI 0.94–
1.22]; P = 0.16) during a median follow-
up of 5.5 years (range 4.2–7.3 years). In
the Nutritional Prevention of Cancer
(NPC) trial, 200 mg/day Se supplementa-
tion with a bioformed yeast did not pre-
vent T2DM (97 cases; RR 1.50 [95% CI
0.98–2.30]) during 7.7 6 2.7 years of
follow-up (13).
There are several potential explana-
tions for the discrepant ﬁndings between
our two prospective cohorts and these
two Se clinical trials. First, toenail Se
levels in our subjects largely represented
modest Se exposure from the diet, with
very few participants taking Se supple-
ments. In contrast, the trials evaluated the
effects of relatively large Se dosages (200
mg/day) from supplements. Approxi-
mately 40% of our study populations re-
ported use of a general multivitamin
supplement, which in some cases could
contain low amounts of Se, but these ex-
posures are small and multivitamin use
has not been associated with toenail Se
levels in these cohorts (30). Of note, doses
of Se in multivitamin supplements used in
the 1980s in these cohorts may be differ-
ent (probably lower) compared with what
may be found on the market today. High
levels of Se consumption from supple-
ments may have different effects than
those ofmodest dietary doses. For example,
in a recent randomized trial, typical sup-
plement doses of antioxidants inhibited
the normal pro-oxidant exercise responses
of muscles, with consequent inhibition
of the beneﬁcial effects of exercise on in-
sulin sensitivity (31). Supradietary doses
of antioxidants may therefore inhibit as-
pects of normal oxidant stress functions,
which may be necessary for optimal phys-
iological responses, including at least
some responses central to preventing
insulin resistance. This may be partic-
ularly relevant for Se, in which typical
dietary doses may be protective by aug-
menting antioxidant defenses but with a
relatively narrow safety range toward tox-
icity (32).
The discrepant ﬁndings between our
prospective cohorts and the two Se clin-
ical trials could also be due to confound-
ing factors in our analyses. For example,
other dietary factors in foods that contain
Se could protect against T2DM (i.e., the
observed protection is due to diet but not
to Se per se), or individuals who consume
higher levels of Se could have other,
nondietary lifestyle behaviors that protect
against T2DM. We adjusted for multiple
dietary and other lifestyle behaviors in-
dependently associated with T2DM risk
in these cohorts, and such adjustment
actually strengthened the results. Never-
theless, residual confounding due to un-
measured or imperfectlymeasured factors
cannot be fully excluded.
Finally, it is possible that effects of Se
on T2DM risk may depend on the speciﬁc
types of Se consumed or on the underly-
ing population characteristics. The prior
trials tested the effects of Se in speciﬁc
dosage forms (e.g., L-selenomethionine in
SELECT, Se–bioformed yeast in NPC)
rather than the more diverse types of Se
derived from foods. Several lines of evi-
dence suggest that puriﬁed nutrients may
not always have the same biological ef-
fects as nutrients obtained within foods
(33,34). The Se trials also enrolled spe-
ciﬁc high-risk populations (e.g., patients
with nonmelanoma skin cancer or at
higher risk for prostate cancer), whereas
our cohorts included generally healthy
Table 2dHazard ratio (95% CI) for T2DM risk according to toenail Se level in the NHS and the HPFS cohorts
Quintiles of toenail Se levels
P1st 2nd 3rd 4th 5th
HPFS
Model 1 1 1.07 (0.78–1.48) 0.74 (0.52–1.06) 0.74 (0.52–1.05) 0.70 (0.49–1.00) 0.01
Model 2 1 1.08 (0.78–1.50) 0.78 (0.54–1.13) 0.78 (0.54–1.13) 0.75 (0.51–1.10) 0.047
Model 3 1 1.07 (0.77–1.49) 0.79 (0.54–1.14) 0.78 (0.54–1.14) 0.76 (0.51–1.11) 0.056
NHS
Model 1 1 0.88 (0.65–1.18) 0.92 (0.69–1.23) 0.85 (0.63–1.14) 0.96 (0.72–1.28) 0.8
Model 2 1 0.82 (0.61–1.11) 0.81 (0.60–1.09) 0.70 (0.51–0.95) 0.80 (0.59–1.07) 0.1
Model 3 1 0.80 (0.59–1.08) 0.78 (0.58–1.06) 0.68 (0.49–0.92) 0.77 (0.57–1.04) 0.08
Pooled results
Model 1 1 0.96 (0.77–1.19) 0.84 (0.67–1.05) 0.80 (0.64–1.00) 0.85 (0.68–1.06) 0.07
Model 2 1 0.93 (0.74–1.16) 0.80 (0.63–1.00) 0.73 (0.58–0.93) 0.78 (0.61–0.98) 0.02
Model 3 1 0.91 (0.73–1.14) 0.78 (0.62–0.99) 0.72 (0.57–0.91) 0.76 (0.60–0.97) 0.01
Model 1: adjusted for age (5-year categories), sex, and future case-control status. Model 2: further adjusted for geographic region (West, Midwest/North, South,
Midwest/South, Northeast, and other), smoking (never, past, and current: 1–14, 15–34, and $35 cigarettes/day), alcohol intake (quintiles), physical activity (sex-
speciﬁc quintiles), BMI (,22, 22–23, 24–26, 27–30, and$30 kg/m2), Se supplement use, and multivitamin use. Model 3: further adjusted for consumption of total
energy (quintiles), the ratio of polyunsaturated to saturated fats (quintiles), trans fat (quintiles), whole grains (quintiles), and coffee (quintiles).
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Figure 1dRRs (95% CI) for the relationship between toenail Se level and incidence of T2DM among men in the HPFS (1986–2008) and women in
the NHS (1982–2008), evaluated using restricted cubic splines, adjusting for age, sex, future case-control status, geographic region, smoking,
alcohol intake, physical activity, BMI, Se supplement use, multivitamin use, and consumption of total energy, ratio of polyunsaturated to saturated
fat, trans fat, whole grain, and coffee. Solid lines, RR; dashed lines, 95% CI.
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men and women, and it is possible that Se
may have different effects depending on
disease stage or other population char-
acteristics. Such explanations, i.e., bi-
ological effect modiﬁcation by the Se
source or by the underlying population
characteristics, should generally be con-
sidered speculative until conﬁrmed by
additional prospective studies, clinical tri-
als, or experiments.
Our study has several strengths. We
evaluated the longitudinal associations
between toenail Se concentrations, an objec-
tive biomarker of long-term Se consump-
tion, and future development of T2DM in
Figure 1dContinued
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two large well-established cohorts includ-
ing both men and women. This represents
the ﬁrst prospective investigation of this
relationship. Thus, our results provide the
best evidence to date of how habitual Se
intake from dietary sources may inﬂuence
the onset of T2DM. Low loss to follow-up
and centralized adjudication of outcomes
reduced the likelihood of missed or mis-
classiﬁed T2DM outcomes. We adjusted
formultiple demographic, lifestyle, and die-
tary covariates, which were assessed using
validated questionnaires to minimize re-
sidual confounding.
Potential limitations should be con-
sidered. Participants were mostly Cauca-
sian and of higher education and income,
which reduced confounding due to race
or socioeconomic status but could limit
generalizability to other populations if
the biological effects of Se on T2DM
vary substantially among different races
or socioeconomic classes. While toenail
Se is a valid measure of dietary Se, there is
no accepted single optimal metric for
assessing Se status overall, in the circula-
tion, or in speciﬁc tissues. Other potential
metrics of Se status were not available in
these cohorts, and the functional relevance
of toenail Se concentrations is uncertain.
While we adjusted for demographic, life-
style, and dietary characteristics, residual
confounding effects from unmeasured
or incompletely measured factors cannot
be excluded. Se levels were assessed at
baseline, and changes in consumption over
time would result in exposure misclassiﬁ-
cation and attenuate results toward the
null.
In conclusion, our ﬁndings suggest
that higher toenail Se, a biomarker of die-
tary Se consumption, is associated with
lower incidence of T2DM among generally
healthy U.S. men and women. Our ﬁnd-
ings do not exclude the possibility of no
beneﬁt or even harm of larger supple-
ment doses, which may, for example,
block normal oxidant stress pathways es-
sential to optimal physiological function.
Our results support the need for further
investigations into the effects of Se, at both
dietary and higher doses, on metabolic
pathways and risk factors for T2DM.
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